Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
Background Recent studies have demonstrated that earlier time-of-day infusion of immune checkpoint inhibitors (ICIs) is associated with longer progression-free survival (PFS) and overall survival (OS) among patients with metastatic melanoma and non-small cell lung cancer. These data are in line with...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-03-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/3/e008011.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850113897291317248 |
|---|---|
| author | Haydn Kissick Viraj A Master Mehmet A Bilen Zachary S Buchwald Mohammad K Khan Caroline S Jansen Michael C Lowe Jimmy S Patel Yena Woo Amber Draper Jennifer W Carlisle Pasquale F Innominato Francis A Lévi Layla Dhabaan David C Qian |
| author_facet | Haydn Kissick Viraj A Master Mehmet A Bilen Zachary S Buchwald Mohammad K Khan Caroline S Jansen Michael C Lowe Jimmy S Patel Yena Woo Amber Draper Jennifer W Carlisle Pasquale F Innominato Francis A Lévi Layla Dhabaan David C Qian |
| author_sort | Haydn Kissick |
| collection | DOAJ |
| description | Background Recent studies have demonstrated that earlier time-of-day infusion of immune checkpoint inhibitors (ICIs) is associated with longer progression-free survival (PFS) and overall survival (OS) among patients with metastatic melanoma and non-small cell lung cancer. These data are in line with growing preclinical evidence that the adaptive immune response may be more effectively stimulated earlier in the day. We sought to determine the impact of time-of-day ICI infusions on outcomes among patients with metastatic renal cell carcinoma (mRCC).Methods The treatment records of all patients with stage IV RCC who began ICI therapy within a multicenter academic hospital system between 2015 and 2020 were reviewed. The associations between the proportion of ICI infusions administered prior to noon (denoting morning infusions) and PFS and OS were evaluated using univariate and multivariable Cox proportional hazards regression.Results In this study, 201 patients with mRCC (28% women) received ICIs and were followed over a median of 18 months (IQR 5–30). The median age at the time of ICI initiation was 63 years (IQR 56–70). 101 patients (50%) received ≥20% of their ICI infusions prior to noon (Group A) and 100 patients (50%) received <20% of infusions prior to noon (Group B). Across the two comparison groups, initial ICI agents consisted of nivolumab (58%), nivolumab plus ipilimumab (34%), and pembrolizumab (8%). On univariate analysis, patients in Group A had longer PFS and OS compared with those in Group B (PFS HR 0.67, 95% CI 0.48 to 0.94, Punivar=0.020; OS HR 0.57, 95% CI 0.34 to 0.95, Punivar=0.033). These significant findings persisted following multivariable adjustment for age, sex, performance status, International Metastatic RCC Database Consortium risk score, pretreatment lactate dehydrogenase, histology, and presence of bone, brain, and liver metastases (PFS HR 0.70, 95% CI 0.50 to 0.98, Pmultivar=0.040; OS HR 0.57, 95% CI 0.33 to 0.98, Pmultivar=0.043).Conclusions Patients with mRCC may benefit from earlier time-of-day receipt of ICIs. Our findings are consistent with established mechanisms of chrono-immunology, as well as with preceding analogous studies in melanoma and lung cancer. Additional prospective randomized trials are warranted. |
| format | Article |
| id | doaj-art-daa2d9d9173340d48a63f3613635074f |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-daa2d9d9173340d48a63f3613635074f2025-08-20T02:37:02ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-03-0112310.1136/jitc-2023-008011Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysisHaydn Kissick0Viraj A Master1Mehmet A Bilen2Zachary S Buchwald3Mohammad K Khan4Caroline S Jansen5Michael C Lowe6Jimmy S Patel7Yena Woo8Amber Draper9Jennifer W Carlisle10Pasquale F Innominato11Francis A Lévi12Layla Dhabaan13David C Qian14Winship Cancer Institute of Emory University, Atlanta, Georgia, USAWinship Cancer Institute of Emory University, Atlanta, Georgia, USAWinship Cancer Institute of Emory University, Atlanta, Georgia, USA1 Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USADepartment of Radiation Oncology, Emory University, Atlanta, Georgia, USA4 Emory University School of Medicine, Atlanta, Georgia, USA8 Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA1 Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA2 University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA3 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA3 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA5 Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK5 Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK6 Emory University, Atlanta, Georgia, USA1 Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USABackground Recent studies have demonstrated that earlier time-of-day infusion of immune checkpoint inhibitors (ICIs) is associated with longer progression-free survival (PFS) and overall survival (OS) among patients with metastatic melanoma and non-small cell lung cancer. These data are in line with growing preclinical evidence that the adaptive immune response may be more effectively stimulated earlier in the day. We sought to determine the impact of time-of-day ICI infusions on outcomes among patients with metastatic renal cell carcinoma (mRCC).Methods The treatment records of all patients with stage IV RCC who began ICI therapy within a multicenter academic hospital system between 2015 and 2020 were reviewed. The associations between the proportion of ICI infusions administered prior to noon (denoting morning infusions) and PFS and OS were evaluated using univariate and multivariable Cox proportional hazards regression.Results In this study, 201 patients with mRCC (28% women) received ICIs and were followed over a median of 18 months (IQR 5–30). The median age at the time of ICI initiation was 63 years (IQR 56–70). 101 patients (50%) received ≥20% of their ICI infusions prior to noon (Group A) and 100 patients (50%) received <20% of infusions prior to noon (Group B). Across the two comparison groups, initial ICI agents consisted of nivolumab (58%), nivolumab plus ipilimumab (34%), and pembrolizumab (8%). On univariate analysis, patients in Group A had longer PFS and OS compared with those in Group B (PFS HR 0.67, 95% CI 0.48 to 0.94, Punivar=0.020; OS HR 0.57, 95% CI 0.34 to 0.95, Punivar=0.033). These significant findings persisted following multivariable adjustment for age, sex, performance status, International Metastatic RCC Database Consortium risk score, pretreatment lactate dehydrogenase, histology, and presence of bone, brain, and liver metastases (PFS HR 0.70, 95% CI 0.50 to 0.98, Pmultivar=0.040; OS HR 0.57, 95% CI 0.33 to 0.98, Pmultivar=0.043).Conclusions Patients with mRCC may benefit from earlier time-of-day receipt of ICIs. Our findings are consistent with established mechanisms of chrono-immunology, as well as with preceding analogous studies in melanoma and lung cancer. Additional prospective randomized trials are warranted.https://jitc.bmj.com/content/12/3/e008011.full |
| spellingShingle | Haydn Kissick Viraj A Master Mehmet A Bilen Zachary S Buchwald Mohammad K Khan Caroline S Jansen Michael C Lowe Jimmy S Patel Yena Woo Amber Draper Jennifer W Carlisle Pasquale F Innominato Francis A Lévi Layla Dhabaan David C Qian Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis Journal for ImmunoTherapy of Cancer |
| title | Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis |
| title_full | Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis |
| title_fullStr | Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis |
| title_full_unstemmed | Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis |
| title_short | Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis |
| title_sort | impact of immunotherapy time of day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma a multicenter cohort analysis |
| url | https://jitc.bmj.com/content/12/3/e008011.full |
| work_keys_str_mv | AT haydnkissick impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT virajamaster impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT mehmetabilen impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT zacharysbuchwald impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT mohammadkkhan impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT carolinesjansen impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT michaelclowe impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT jimmyspatel impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT yenawoo impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT amberdraper impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT jenniferwcarlisle impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT pasqualefinnominato impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT francisalevi impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT layladhabaan impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis AT davidcqian impactofimmunotherapytimeofdayinfusiononsurvivalandimmunologiccorrelatesinpatientswithmetastaticrenalcellcarcinomaamulticentercohortanalysis |